We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Little Follow-up After Positive Test for Colon Cancer

By HospiMedica staff writers
Posted on 09 Jun 2006
A new study has found that more than 40% of patients who received a positive result on a fecal occult blood test (FOBT) did not receive appropriate diagnostic follow-up tests such as a colonoscopy or barium enema.

Researchers at the University of California, Los Angeles (UCLA, USA), and the U.S. More...
Department of Veteran's Affairs (VA, Washington, DC) analyzed the records of 39,870 veteran patients. Of these, 61% of eligible VA patients had been screened for colorectal cancer, which is significantly higher than the U.S. national average. Out of those screened, 313 patients had an abnormal FOBT result. However, only 59% (185) of these patients received follow-up diagnostic tests such as a colonoscopy or a barium enema. The remaining 41% (128) of these patients received no follow-up at all in the six months following the FOBT.

The researchers noted several reasons why patients did not receive any follow-up. Some did not have a primary care visit with a doctor in the six months following the screening, and the others, while they saw a doctor during the six months, were not referred for a follow-up colonoscopy. Potential solutions include educating patients to advocate for screening and follow-up and using electronic systems to track follow-up. The findings were published in the May 2006 edition of Diseases of the Colon & Rectum.

"Traditionally, quality-of-care assessments just look at initial screening rates for colon cancer, but this study reveals that efforts should focus on the entire diagnostic process to help ensure that patients don't slip through the cracks in the system,” said Dr. David A. Etzioni, principal investigator and a clinical scholar in the division of general surgery at the David Geffen School of Medicine at UCLA.



Related Links:
UCLA
Veterans' Affairs

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Rapid Sepsis Test
SeptiCyte RAPID
Wound Irrigation Solution
Prontosan®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.